Literature DB >> 27418106

Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.

Lysanne A Lievense1, Robin Cornelissen2, Koen Bezemer2, Margaretha E H Kaijen-Lambers2, Joost P J J Hegmans2, Joachim G J V Aerts3.   

Abstract

INTRODUCTION: Clinical studies have demonstrated beneficial effects of immunotherapy in malignant pleural mesothelioma. The pleural cavity seems an attractive compartment to administer these types of therapies; however, local immunosuppressive mechanisms could hamper their efficacy. Macrophages are abundantly present within the mesothelioma microenvironment. This study investigates the influence of the macrophage phenotype, macrophages' capacity to inhibit local immune responses, and the decisive role of pleural effusion (PE) in this regard.
METHODS: We cultured macrophages in the presence of PEs and investigated their phenotype. Macrophages and T cells were cocultured in the presence of PEs and tumor cell line supernatants. The levels of 11 cytokines and the prostanoid prostaglandin E2 were measured in PEs and supernatants. The presence and phenotype of macrophages and T cell subsets was measured in the PE of patients with mesothelioma.
RESULTS: PE induced a tumor-promoting M2 phenotype in macrophages, which was confirmed by the suppressive activity of macrophages on T cell proliferation during coculture. Prostanoid prostaglandin E2 was identified as a potential inducer of the suppressive capacity of macrophages in PE. Macrophages isolated from PEs displayed an M2 phenotype and were negatively correlated with T cells in vivo.
CONCLUSIONS: The current study demonstrates that macrophages in PE can play a pivotal role in directly hampering the antitumor T cell immune response. This emphasizes the potential of macrophages as a therapeutic target in mesothelioma and indicates that the presence and phenotype of macrophages in PE should be taken into consideration in the application of (intrapleural) immunotherapies.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunosuppression; Mesothelioma; Microenvironment; Pleural cavity; Tumor-associated macrophages

Mesh:

Year:  2016        PMID: 27418106     DOI: 10.1016/j.jtho.2016.06.021

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  26 in total

Review 1.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

2.  Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.

Authors:  Saly Al-Taei; Josephine Salimu; Lisa K Spary; Aled Clayton; Jason F Lester; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2016-12-08       Impact factor: 8.110

3.  Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

Authors:  Pietro Bertino; Thomas A Premeaux; Tsuyoshi Fujita; Brien K Haun; Michael P Marciel; Fukun W Hoffmann; Alan Garcia; Haining Yiang; Sandra Pastorino; Michele Carbone; Toshiro Niki; John Berestecky; Peter R Hoffmann; Lishomwa C Ndhlovu
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

Review 4.  Novel insights into mesothelioma biology and implications for therapy.

Authors:  Timothy A Yap; Joachim G Aerts; Sanjay Popat; Dean A Fennell
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

Review 5.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

Review 6.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609

7.  Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.

Authors:  Beatrice Dozin; Grazia Carbotti; Silvio Roncella; Paola Ferro; Paolo Dessanti; Pier Aldo Canessa; Silvano Ferrini; Marina Fabbi
Journal:  Cancer Immunol Immunother       Date:  2021-05-18       Impact factor: 6.968

Review 8.  Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?

Authors:  Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

9.  Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.

Authors:  Silvia Mola; Giulia Pinton; Marco Erreni; Marco Corazzari; Marco De Andrea; Ambra A Grolla; Veronica Martini; Laura Moro; Chiara Porta
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 10.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.